EGFR and pancreatic adenocarcinoma: Since the inhibition of a single ERBB receptor seems insufficiently effective in treating pancreatic adenocarcinoma, our study provides evidence that inhibiting pan‐ERBB‐signaling by trapping all ERBB ligands is a more promising approach.